Paratek expands commercial portfolio with Optinose

Paratek Pharmaceuticals has acquired Optinose for nearly $330 million, enhancing its commercial portfolio. The deal includes all outstanding shares of Optinose and contingent value rights based on Xhance's sales performance. Paratek will pay $1 per share if Xhance achieves $150 million in net sales by 2028, and an additional $4 per share if it reaches $225 million by 2029. This acquisition aims to position Paratek as a multi-product specialty therapeutics company, addressing unmet medical needs.

OptiNose Inc. Conducted Special Stockholder Meeting

OptiNose Inc. Conducted Special Stockholder Meeting OptiNose Inc. held a special meeting of stockholders on May 16, 2025. During the meeting, stockholders voted on a proposal to adopt the Agreement and Plan of Merger with Paratek Pharmaceuticals, Inc. and Orca Merger Sub, Inc. This proposal was approved. Additionally, a proposal to approve adjournments of the Special Meeting, if necessary, was deemed unnecessary and was not submitted for approval.

OptiNose Inc reports results for the quarter ended March 31 - Earnings Summary

OptiNose Inc reported a quarterly adjusted loss of $1.92 per share for the quarter ended March 31, compared to a loss of $1.80 in the same quarter last year. Revenue increased by 24.4% to $18.51 million, exceeding analyst expectations of $17.70 million. The average analyst rating is "buy," with a median 12-month price target of $9.00. OptiNose shares rose 3.1% this quarter and 41.5% year-to-date. Analysts have not revised earnings estimates in the last 30 days.

Optinose | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 18.51 M

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in OptiNose, Inc. (NASDAQ:OPTN) by 94.4% in Q4, now holding 12,748 shares valued at $85,000. In contrast, Geode Capital Management increased its stake by 33.7%. CEO Ramy A. Mahmoud sold 6,376 shares, decreasing his ownership by 4.78%. OptiNose's stock opened at $9.40, with a market cap of $95.19 million. Analysts have downgraded their target prices, with Piper Sandler and HC Wainwright setting a target of $9.00. The company reported earnings of ($0.03) per share, exceeding estimates.